Drug Trial Radar · NCT05433506
Safety and Pharmacokinetics of HU6
Last checked: Nov 19, 2026Latest source record: Mar 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 15, 2022
Primary completion
Jan 30, 2023
Study completion Mar 15, 2023
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as the tablet formulation. Eight subjects will be enrolled to participate in all of the ascending study periods.
Conditions
- Obese
Interventions
HU6 TabletDrug
Six subjects will receive a tablet formulation.
HU6 CapsuleDrug
Six subjects will receive the capsule formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the dose relationship of PK Parameter CmaxTime frame: 150 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.